Thank you Hottod & Sillaze, Little T for your posts and the discussion which derives from these posts. I have been following this company for a while now and I have to say I am impressed of what they have achieved so far. Yet it is obvious that the market is not feeling the same appreciation of the advancements this company has done in the last couple of months.
I am aware of the current situation of the company and fully agree to the posted trigger points (e.g. successful Phase 3, etc.). However I struggle to find the reason why big institutions are not chipping in. At one point, even if there is some remaining risk, you have to take a bet and invest or you don't. As a matter of fact, I am not sure why big insto's wouldn't want a piece of this company now. The AUS $ is dirt cheap, the SP got hammered and is at a good buy-in price. From an investment risk perspective (lets say you manage a portfolio as a investment banker), I would certainly put some serious money into this stock.
Or are they waiting for the opportune moment? And when would that be? Are they waiting for a successful Phase 3? Nothing is certain in clinical trials, however I for myself, have never seen such a big commitment from patient advocacy groups in favor for a drug! This is for me really a key driver!
Can anyone from the top posters here (Hottod, Little T etc.), comment on this following question: How much do you believe the patient advocacy groups can influence the FDA decision. Given that Phase 3 clinical data remain as positive as Phase 2 and worse case, less clinically relevant than in the Phase 2. However it is still safe to use and shows some clinical benefit for the patient.
In my book the families & patients still have "the right to try", dont you think?
NEU Price at posting:
$1.68 Sentiment: Buy Disclosure: Held
(20min delay)